Hypotony in Patients with Uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial

National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Ocular immunology and inflammation (Impact Factor: 1.97). 04/2012; 20(2):104-12. DOI: 10.3109/09273948.2011.647228
Source: PubMed

ABSTRACT To assess the prevalence of hypotony in patients with severe forms of uveitis.
The Multicenter Uveitis Steroid Treatment (MUST) Trial, a randomized study, enrolled 255 patients. Patients with hypotony at the baseline visit were identified.
Twenty (8.3%) of 240 patients with sufficient data had hypotony. Hypotony was more common in patients with uveitis ≥5 years duration (odds ratio [OR] = 5.0; p < .01), and in eyes with a history of ocular surgery (vitrectomy vs. none, OR = 3.1; p = .03). Hypotony was less in patients with older age of uveitis onset (>51 years vs. <51 years, OR = 0.1; p = .02), in Caucasian patients (OR = 0.1; p < .01) compared to African American patients. Hypotonous eyes were more likely to have visual impairment (OR = 22.9; p < .01).
Hypotony is an important complication of uveitis and more commonly affects African-American patients, those with uveitis onset at a younger age, and those with longer disease duration. It is associated with visual impairment.

Download full-text


Available from: Douglas A Jabs, Aug 25, 2014
1 Follower
86 Reads
  • Source
    • "Uveitis, a common cause of vision loss, accounts for 5% to 15% of all cases of blindness worldwide affecting individuals of all ages, both sexes, and all races [3]. Possible complications of chronic uveitis include glaucoma, cataracts, accumulation of fluids within the retina, retinal detachment and vision loss [4] [5]. Therefore, control of inflammation in uveitis is critical to minimize the vision loss. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of the present study was to develop and optimize sinomenine hydrochloride (SIN) in situ gel for uveitis treatment. Methods: Carbopol 940 was used as the gelling agent in combination with hydroxypropyl methylcellulose (HPMC), which acts as a viscosity enhancer. The formulations were prepared using various concentrations of Carbopol 940 and HPMC. The prepared in situ gels were evaluated for gellation, drug release, ocular irritation, elimination time and pharmacokinetic studies. Furthermore, the effect of SIN on the development of experimental autoimmune anterior uveitis (EAAU) was assessed. Results: The optimum concentration of Carbopol was 0.1% (w/v), and that for HPMC was 0.4% (w/v). Which showed a significant enhancement in gel strength in the physiological condition while free flowing at non-physiological condition. Optimum formula F(2-3) consisting of 0.5% SIN was prepared and kept as gel group, and 0.5% SIN solution was prepared and kept as control group. Gel group provided sustained release of the drug over a period of 480 min. No evidence of overt toxicity and irritation was observed in any study. The elimination time of control group and gel group was completed within 10 min and 25 min, respectively. The area under the aqueous humor concentration vs. time curve (AUC(0-t)) and maximum concentration (C(max)) values of gel group was 2.70-fold and 1.79-fold higher than that of control group. Additionally, clinical examination showed that SIN suppressed inflammation in EAAU. Conclusions: These results support the potential applications of SIN in situ gel for uveitis treatment.
    International immunopharmacology 06/2013; 17(1). DOI:10.1016/j.intimp.2013.05.020 · 2.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this interventional case series, two eyes of two patients with diabetic macular oedema and one eye of a patient with complicated cataract secondary to uveitis associated with juvenile idiopathic arthritis had inadvertent injection of dexamethasone implant into the capsular bag. This was followed by successful completion of phacoemulsification and intraocular lens implantation. At 1-year follow-up, all patients maintained visual acuity of ≥20/40 with absence of macular oedema.
    Case Reports 12/2012; 2012. DOI:10.1136/bcr-2012-007494
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Endogenous anterior uveitis (AU), when untreated, may lead to vision loss. This study compared the safety and efficacy of difluprednate versus prednisolone acetate for the treatment of this condition. Methods: This phase III, double-masked, noninferiority study randomized patients with mild to moderate endogenous AU to receive difluprednate 0.05% (n = 56) four times daily, alternating with vehicle four times daily, or prednisolone acetate 1% (n = 54) eight times daily. The 14-day treatment period was followed by a 14-day dose-tapering period and a 14-day observation period. The primary efficacy end point was change in anterior chamber cell grade (range, 0 for ≤1 cell to 4 for >50 cells) from baseline to day 14. Results: At day 14, the mean change in anterior chamber cell grade with difluprednate was noninferior to that with prednisolone acetate (-2.2 vs. -2.0, P = 0.16). The proportions of difluprednate-treated patients versus prednisolone acetate-treated patients demonstrating complete clearing of anterior chamber cells at day 3 were 13.0% vs. 2.1% (P = 0.046) and at day 21 were 73.9% vs. 63.8% (P = 0.013). A significant between-group difference in the mean IOP increase was seen at day 3 (2.5 mm Hg for difluprednate-treated patients and 0.1 mm Hg for prednisolone acetate-treated patients, P = 0.0013) but not at other time points. The mean IOP values in both groups remained less than 21 mm Hg throughout the study. Conclusions: Difluprednate 0.05% four times daily is well tolerated and is noninferior to prednisolone acetate 1% eight times daily for the treatment of endogenous AU. ( number, NCT01201798.).
    Investigative ophthalmology & visual science 03/2014; 55(5). DOI:10.1167/iovs.13-12660 · 3.40 Impact Factor
Show more